Evoke Pharma (EVOK)

Evoke Pharma is an advanced-clinical stage pharmaceutical company focused on discovering, development and commercialization of EVK-001 as a potential treatment of diabetic gastroparesis.  EVK-001 is an intranasally delivered metoclopramide for the purpose of treating gastroparesis by circumventing the shortcoming – reduced treatment impact caused by unpredictable drug absorption – of the current oral metoclopramide-based treatment. The company expects to commence a Phase III pivotal study in 2Q14 and expect to report top-line results in late 2H15.  As such, EVK-001 could potential reach market in late 2016.